- Home
- AAUC vs EWTX Comparison
AAUC vs EWTX Comparison
Compare AAUC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAUC
- EWTX
- Stock Information
- Founded
- AAUC N/A
- EWTX 2017
- Country
- AAUC Canada
- EWTX United States
- Employees
- AAUC N/A
- EWTX N/A
- Industry
- AAUC
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- AAUC
- EWTX Health Care
- Exchange
- AAUC Nasdaq
- EWTX Nasdaq
- Market Cap
- AAUC 1.7B
- EWTX 1.4B
- IPO Year
- AAUC N/A
- EWTX 2021
- Fundamental
- Price
- AAUC $13.63
- EWTX $13.71
- Analyst Decision
- AAUC
- EWTX Buy
- Analyst Count
- AAUC 0
- EWTX 9
- Target Price
- AAUC N/A
- EWTX $39.89
- AVG Volume (30 Days)
- AAUC 74.4K
- EWTX 791.6K
- Earning Date
- AAUC 08-08-2025
- EWTX 08-07-2025
- Dividend Yield
- AAUC N/A
- EWTX N/A
- EPS Growth
- AAUC N/A
- EWTX N/A
- EPS
- AAUC N/A
- EWTX N/A
- Revenue
- AAUC $901,722,000.00
- EWTX N/A
- Revenue This Year
- AAUC $72.24
- EWTX N/A
- Revenue Next Year
- AAUC $28.54
- EWTX N/A
- P/E Ratio
- AAUC N/A
- EWTX N/A
- Revenue Growth
- AAUC 33.30
- EWTX N/A
- 52 Week Low
- AAUC $12.84
- EWTX $10.60
- 52 Week High
- AAUC $15.79
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- AAUC N/A
- EWTX 47.19
- Support Level
- AAUC N/A
- EWTX $12.51
- Resistance Level
- AAUC N/A
- EWTX $14.30
- Average True Range (ATR)
- AAUC 0.00
- EWTX 0.67
- MACD
- AAUC 0.00
- EWTX 0.06
- Stochastic Oscillator
- AAUC 0.00
- EWTX 58.15
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.